Use of Human Intravenous Immunoglobulin Therapy in Two Dogs with Non-Neoplastic Bone Marrow Disorders Refractory to Immunosuppressive Therapy.

ABSTRACT: Immune-mediated non-neoplastic bone marrow disorders (NNBMD), including precursor-targeted immune-mediated anemia (PIMA) and myelodysplastic syndrome (MDS), can cause non-regenerative anemia in dogs and often fail to respond to immunosuppressive treatment. Human intravenous immunoglobulin (hIVIG) has been proposed as an immunomodulatory therapy for refractory hematologic disease in humans, but evidence in veterinary patients remains limited. This case report describes the adjunctive use of hIVIG and the associated clinical responses observed in two dogs with refractory NNBMD. A 10-year-old (3.2 kg) spayed female Maltese (case 1) showed persistent non-regenerative anemia, with hematocrit (HCT) 15.6-20.2% and reticulocyte production index (RPI) 0.12-0.69, requiring four transfusions over 10

SUBMITTER: Kim EJ 

PROVIDER: S-EPMC12945045 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature